Evidence map›Paper›PMID 32377946›Full record

ArticleJournal of gastroenterology2020

Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants.

Kenji Watanabe, Satoshi Tanida, Nagamu Inoue, Reiko Kunisaki, Kiyonori Kobayashi, Masakazu Nagahori, Katsuhiro Arai, Motoi Uchino, Kazutaka Koganei, Taku Kobayashi and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Treat-to-target in Behçet syndrome.Nature reviews. Rheumatology · 2026
    Review
  4. Article
  5. Article
  6. Management of Severe Behçet's Disease.Current rheumatology reports · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  17. Review
  18. Article
  19. Article
  20. The treatment principles and targets for intestinal Behcet's disease.Therapeutic advances in gastroenterology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 1 country.

Kenji WatanabeDepartment of Intestinal Inflammation Research, Hyogo College of Medicine, Hyogo, Japan.
Satoshi TanidaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
Nagamu InoueCenters for Preventive Medicine, Keio University School of Medicine, Tokyo, Japan.
Reiko KunisakiInflammatory Bowel Disease Center, Yokohama City University Medical Center, Kanagawa, Japan.
Kiyonori KobayashiResearch and Development Center for New Medical Frontiers, Kitasato University, School of Medicine, Kanagawa, Japan.
Masakazu NagahoriDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
Katsuhiro AraiDivision of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
Motoi UchinoDepartment of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Hyogo, Japan.
Kazutaka KoganeiDepartment of Inflammatory Bowel Disease, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
Taku KobayashiCenter for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Mitsuhiro TakenoDepartment of Allergy and Rheumatology, Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan.
Fumiaki UenoCenter for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kanazawa, Japan.
Takayuki MatsumotoDivision of Gastroenterology, Department of Medicine, Iwate Medical University, Iwate, Japan.
Nobuhisa MizukiDepartment of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Yasuo SuzukiInflammatory Bowel Disease Center, Toho University Sakura Medical Center, Chiba, Japan.
Tadakazu HisamatsuDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan. thisamatsu@ks.kyorin-u.ac.jp.
Hyogo Medical University · JPIwate Medical University · JPKeio University · JPKitasato Institute Hospital · JPKitasato University · JPKyorin University · JPNagoya City University · JPNational Center For Child Health and Development · JPNippon Medical School Musashi Kosugi Hospital · JPToho University Medical Center Sakura Hospital · JPTokyo Medical and Dental University · JPYokohama City University · JPYokohama City University Medical Center · JPYokohama Municipal Citizen's Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Behçet's disease (BD) is an intractable systemic inflammatory disease characterized by four main symptoms: oral and genital ulcers and ocular and cutaneous involvement. The Japanese diagnostic criteria of BD classify intestinal BD as a specific disease type. Volcano-shaped ulcers in the ileocecum are a typical finding of intestinal BD, and punched-out ulcers can be observed in the intestine or esophagus. Tumor necrosis factor inhibitors were first approved for the treatment of intestinal BD in Japan and have been used as standard therapy. In 2007 and 2014, the Japan consensus statement for the diagnosis and management of intestinal BD was established. Recently, evidence-based JSBD (Japanese Society for BD) Clinical Practice Guidelines for BD (Japanese edition) were published, and the section on intestinal BD was planned to be published in English. Twenty-eight important clinical questions (CQs) for diagnosis (CQs 1-6), prognosis (CQ 7), monitoring and treatment goals (CQs 8-11), medical management and general statement (CQs 12-13), medical treatment (CQs 14-22), and surgical treatment (CQs 23-25) of BD and some specific situations (CQs 26-28) were selected as unified consensus by the members of committee. The statements and comments were made following a search of published scientific evidence. Subsequently, the levels of recommendation were evaluated based on clinical practice guidelines in the Medical Information Network Distribution Service. The degree of agreement was calculated using anonymous voting. We also determined algorithms for diagnostic and therapeutic approaches for intestinal BD. The present guidelines will facilitate decision making in clinical practice.

Indexed as

Practice Guidelines as TopicAlgorithmsBehcet SyndromeEvidence-Based MedicineHumansIntestinal DiseasesJapanPrognosisTumor Necrosis Factor InhibitorsTumor Necrosis Factor InhibitorsBehçet’s diseaseConsensusEvidenceGuidelineIntestinal behçet’s disease

Identifiers

PMID32377946
PMCPMC7297851
OpenAlexW3023833932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.